Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Next Previous
Trial Profile

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nibrozetone (Primary) ; Bevacizumab; Irinotecan; Regorafenib
  • Indications Adenocarcinoma; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms ROCKET
  • Sponsors EpicentRx

Most Recent Events

  • 21 Jan 2023 Results (n=34) comparing the safety and efficacy of the combination therapy RRx-001 + irinotecan vs. regorafenib + irinotecan in 3rd/4th line colorectal cancer , presented at the 2023 Gastrointestinal Cancers Symposium
  • 20 Jan 2023 According to an EpicentRx media release, this study was carried out in collaboration with Dr. Keola Beale from Kaiser Permanente Moanalua Medical Center.
  • 20 Jan 2023 According to an EpicentRx media release, data from this study will be presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top